Q4 revenue -- $67.3 million reported for the quarter ended Dec. 31, 2025, compared to $1.5 million in Q4 2024; increase driven primarily by AstraZeneca and Gilead (NASDAQ:GILD) payments. Full-year ...
Q4 2025 Earnings Call March 2, 2026 8:30 AM ESTCompany ParticipantsBrandon Sim - President & CEOChan Basho - CFO, COO ...
DexCom, Inc. (DXCM) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 1:05 PM ESTCompany ParticipantsJereme Sylvain - Executive ...
Modern Oral PMTA Spend -- Budgeted at $3 million to $5 million for the year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results